SAFETY AND SPECIFIC ACTIVITY OF THE RECOMBINANT SARS-COV-2 (CORONADERM-PS) ALLERGEN BASED ON PHASE I-II CLINICAL TRIAL RESULTS
- Authors:
Savin T.V.1,2, Milichkina A.M.1, Krasnov A.A.1, Kuznetsova R.N.1,2, Shchederkina E.E.1, Svarval A.V.1, Sharova A.А.1, Reingardt D.E.1, Ostankova Y.V.1, Gubanova A.V.1, Petrova O.A.1,2, Zhimbaeva O.B.1, Razumovskaya A.P.1, Drozd I.V.1, Rubinstein A.А.3, Trulioff A.S.3, Kudryavtsev I.V.2,3, Kopat V.V.4, Dukhovlinov I.V.4, Simbirtsev A.S.1,2, Totolian A.A.1,2
-
Affiliations:
- Saint-Petersburg Pasteur Institute
- Pavlov First Saint Petersburg State Medical University
- Institute of Experimental Medicine, St. Petersburg, Russian Federation
- ATG Service Gene LLC, St. Petersburg, Russian Federation
- Section:
ORIGINAL ARTICLES
- Submitted: 17.10.2024
- Accepted: 23.10.2024
- Published:
Email this article